The aggrecanopathies; An evolving phenotypic spectrum of human genetic skeletal diseases

67Citations
Citations of this article
59Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The large chondroitin sulphated proteoglycan aggrecan (ACAN) is the most abundant non-collagenous protein in cartilage and is essential for its structure and function. Mutations in ACAN result in a broad phenotypic spectrum of non-lethal skeletal dysplasias including spondyloepimetaphyseal dysplasia, spondyloepiphyseal dysplasia, familial osteochondritis dissecans and various undefined short stature syndromes associated with accelerated bone maturation. However, very little is currently known about the disease pathways that underlie these aggrecanopathies, although they are likely to be a combination of haploinsufficiency and dominant-negative (neomorphic) mechanisms. This review discusses the known human and animal aggrecanopathies in the context of clinical presentation and potential disease mechanisms.

Cite

CITATION STYLE

APA

Gibson, B. G., & Briggs, M. D. (2016, June 28). The aggrecanopathies; An evolving phenotypic spectrum of human genetic skeletal diseases. Orphanet Journal of Rare Diseases. BioMed Central Ltd. https://doi.org/10.1186/s13023-016-0459-2

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free